Heinicke, Thomas, Labopin, Myriam, Polge, Emmanuelle, Stelljes, Matthias, Ganser, Arnold, Tischer, Johanna, Brecht, Arne, Kröger, Nicolaus, Beelen, Dietrich W., Scheid, Christof, Bethge, Wolfgang, Dreger, Peter, Bunjes, Donald, Wagner, Eva, Platzbecker, Uwe, Savani, Bipin N., Nagler, Arnon, and Mohty, Mohamad
The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients <55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients ≥55 years LFS was best with FLAMSA-Chemo without significant differences compared to FLAMSA-TBI4 and Mel-Flu-TBI8. Furthermore, best NRM rates were obtained with the two FLAMSA regimens groups. Our study suggests that in younger (<55 years) patients a more intense regimen might be used whereas in older (≥55 years) patients the focus might be more on tolerability. [ABSTRACT FROM AUTHOR]